Biotech companies in Virginia, Maryland and Washington are better served by meeting challenges as a region, industry experts say.
One reason, according to Peter Greenleaf, president of MedImmune, is that as with many other industries, biotech is facing increasing pressure from Asian companies and investors.
In 2011, Maryland Gov. Martin O’Malley appointed Greenleaf chairman of the Maryland Venture Fund Authority. MedImmune is affiliated with AstraZeneca, based in Gaithersburg, Md., and is one of the region’s largest biotech companies.